40th Annual Miami Breast Cancer Conference® - Abstracts

home / journals / mbcc-suppl / 40th-annual-miami-breast-cancer-conference-abstracts
1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer

1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer

Philippe Aftimos;Javier Cortes;Francois Clement Bidard;Virginia Kaklamani, MD, DSc;Aditya Bardia, MD, MPH;Alberto J. Montero;Joo Hyuk Sohn;Giulia Tonini;Krzysztof J. Grzegorzewski;Patrick Neven, MD, PhD
April 28th 2023
ArticleMedical Oncology
2 Molecular Characterization of HER2-Low Patients Identifies Basal-Enriched Subset With Poor Clinical Outcomes in Real-world Data

2 Molecular Characterization of HER2-Low Patients Identifies Basal-Enriched Subset With Poor Clinical Outcomes in Real-world Data

Talal Ahmed;Daniel Stover;Adam Hockenberry;Matthew Mackay;Raphael Pelossof;Halla Nimeiri;James L. Chen;Rotem Ben-Shachar;Massimo Cristofanilli, MD
April 28th 2023
ArticleMedical Oncology
3 Real-world Outcomes of Sacituzumab Govitecan in Metastatic Breast Cancer Patients: A Single Institution Experience

3 Real-world Outcomes of Sacituzumab Govitecan in Metastatic Breast Cancer Patients: A Single Institution Experience

Sabah Alaklabi;Joseph Elijah;Arya Mariam Roy;Adrienne Groman;Shipra Gandhi
April 28th 2023
ArticleMedical Oncology
4 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/ Metastatic Triple-Negative Breast Cancer (a/mTNBC): Updated Results From BEGONIA, a Phase 1b/2 Study

4 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/ Metastatic Triple-Negative Breast Cancer (a/mTNBC): Updated Results From BEGONIA, a Phase 1b/2 Study

Jamil Asselah;Cynthia X. Ma, MD, PhD;Zbigniew Nowecki;Robert Huisden;Ross Stewart;Petra Vuković;Peter Schmid, MD
April 28th 2023
ArticleMedical Oncology
5 Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib Combinations as First- Line Treatment for Advanced or Metastatic Breast Cancer in Realworld Settings in Argentina and Colombia: Results from the IRIS Study

5 Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib Combinations as First- Line Treatment for Advanced or Metastatic Breast Cancer in Realworld Settings in Argentina and Colombia: Results from the IRIS Study

Alexandra Guarin;Katie Mycock;Gary Milligan;Gavin Taylor-Stokes;Christian Atkinson
April 28th 2023
ArticleMedical Oncology
7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

Aditya Bardia, MD, MPH;Francois Clement Bidard;Patrick Neven, MD, PhD;Alberto J. Montero;Joo Hyuk Sohn;Philippe Aftimos;Javier Cortes;Simona Scartoni;Nassir Habboubi;Virginia Kaklamani, MD, DSc
April 28th 2023
ArticleMedical Oncology
8 Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple- Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study

8 Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple- Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study

Aditya Bardia, MD, MPH;Ian E. Krop;Funda Meric-Bernstam, MD;Anthony W. Tolcher;Toru Mukohara;Aaron Lisberg;Toshio Shimizu;Erika P. Hamilton, MD;Alexander Spira, MD, PhD, FACP;Takahiro Kogawa
April 28th 2023
ArticleMedical Oncology
9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

Aditya Bardia, MD, MPH;Ian E. Krop;Dejan Juric;Takahiro Kogawa;Erika P. Hamilton, MD;Alexander Spira, MD, PhD, FACP;Toru Mukohara;Takuya Tsunoda;Senthil Damodaran;Funda Meric-Bernstam, MD
April 28th 2023
ArticleMedical Oncology
11 Real-world Treatment Patterns and Effectiveness of Palbociclib Plus an Aromatase Inhibitor in Patients With Metastatic Breast Cancer Aged 75 Years or Above

11 Real-world Treatment Patterns and Effectiveness of Palbociclib Plus an Aromatase Inhibitor in Patients With Metastatic Breast Cancer Aged 75 Years or Above

Adam M. Brufsky, MD, PhD;Xianchen Liu;Benjamin Li;Lynn McRoy;Connie Chen;Rachel M. Layman;Hope S. Rugo, MD
April 28th 2023
ArticleMedical Oncology
12 TIP HARMONIA SOLTI-2101/ AFT-58: A Head-to-Head Phase III Study Comparing Ribociclib (RIB) and Palbociclib (PAL) in Patients (pts) With Hormone Receptor– Positive/HER2-Negative/HER2- Enriched (HR+/HER2−/HER2-E) Advanced Breast Cancer (ABC)

12 TIP HARMONIA SOLTI-2101/ AFT-58: A Head-to-Head Phase III Study Comparing Ribociclib (RIB) and Palbociclib (PAL) in Patients (pts) With Hormone Receptor– Positive/HER2-Negative/HER2- Enriched (HR+/HER2−/HER2-E) Advanced Breast Cancer (ABC)

Lisa A. Carey, MD;Tomas Pascual;Daniel Stover;Astrid Thuerigen;Charles Perou;Eva Ciruelos;Ana Casas;Patty Spears;Estelle Roux;Faye Su;Hullin Hu;Yen-Shen Lu;Sara M. Tolaney, MD, MPH;Ann H. Partridge, MD, MPH;Guillermo Villacampa;Juan Manuel Ferrero-Cafiero;Aleix Prat
April 28th 2023
ArticleMedical Oncology
13 Improved Sensitivity in Identification of ER- and HER2- Expressing Metastatic Breast Cancers With a Combination of Cell & Cell-Free Liquid Biopsy Analysis

13 Improved Sensitivity in Identification of ER- and HER2- Expressing Metastatic Breast Cancers With a Combination of Cell & Cell-Free Liquid Biopsy Analysis

Giuseppe Di Caro;Ernest Lam;Kandra Horne;Stefan Gluck;Megan Slade;Rick Wenstrup;Lee Schwartzberg, MD, FACP
April 28th 2023
ArticleMedical Oncology
15 Updated Expert Consensus Recommendations for Managing Hyperglycemia and Rash in Patients With PIK3CA-Mutated, Hormone Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2–Negative (HER2–) Advanced Breast Cancer Treated With Alpelisib

15 Updated Expert Consensus Recommendations for Managing Hyperglycemia and Rash in Patients With PIK3CA-Mutated, Hormone Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2–Negative (HER2–) Advanced Breast Cancer Treated With Alpelisib

Emily J. Gallagher;Heather Moore;Mario E. Lacouture, MD;Susan F. Dent;Azeez Farooki, MD;Marcus D. Goncalves;Claudine Isaacs, MD;Abigail Johnston;Dejan Juric;Zoe Quandt;Laura Spring;Brian Berman;Melanie Decker;Gabriel N. Hortobagyi, MD, FACP;Benjamin H. Kaffenberger;Bernice Y. Kwong;Timothy Pluard;Ruta Rao, MD;Lee Schwartzberg, MD, FACP;Michael S. Broder
April 28th 2023
ArticleMedical Oncology
16 Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy

16 Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy

Melissa Gao;Yen-Shen Lu;Eznal Izwadi Bin Mohd Mahidin;Hamdy Abdel Azim;Yesim Eralp;Yoon Sim Yap;Seock-Ah Im;Julie Rihani;James Bowles;Teresa Delgar Alfaro;Jiwen Wu;Khemaies Slimane;Nagi El Saghir
April 28th 2023
ArticleMedical Oncology
17 A Clinical Systematic Literature Review of Treatments Among Patients With Advanced/ Metastatic HER2+ Breast Cancer

17 A Clinical Systematic Literature Review of Treatments Among Patients With Advanced/ Metastatic HER2+ Breast Cancer

Kerigo Ndirangu;Rachel Goldgrub;Vanita Tongbram;Rajee Antony;Bagrat Lalayan;Joyce A. O’Shaughnessy;Sarah E. Schellhorn
April 28th 2023
ArticleMedical Oncology
20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer

20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Erika P. Hamilton, MD;Lajos Pusztai, MD, DPhil;Hatem Soliman, MD;Sara A. Hurvitz, MD;Krzysztof J. Grzegorzewski;Nassir Habboubi;Priya Marreddy;Tarek Sahmoud, MD;Nuhad Ibrahim, MD
April 28th 2023
ArticleMedical Oncology
21 TIP ELECTRA: An Open- Label, Multicenter, Phase 1b/2 Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2– Negative (HER2–) Breast Cancer

21 TIP ELECTRA: An Open- Label, Multicenter, Phase 1b/2 Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2– Negative (HER2–) Breast Cancer

Erika P. Hamilton, MD;Sung-Bae Kim;Neelima Vidula, MD;Simona Scartoni;Tarek Sahmoud, MD;Bartomeu Piza Vallespir;Kathy Puyana Theall;Nassir Habboubi;Nuhad Ibrahim, MD
April 27th 2023
ArticleMedical Oncology
24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study

24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study

Sara A. Hurvitz, MD;Anne F. Schott, MD;Cynthia X. Ma, MD, PhD;Erika P. Hamilton, MD;Rita Nanda, MD;George Zahrah;Natasha Hunter, MD;Antoinette R. Tan;Melinda L. Telli, MD;Jesus Anampa Mesias;Rinath Jeselsohn;Pamela N. Munster, MD;Haolan Lu;Richard Gedrich;Cecile Mather;Janaki Parameswaran;Hyo S Han
April 27th 2023
ArticleMedical Oncology
25 Real-world BRCA1/2 Testing Patterns in HER2–Negative Early- Stage Breast Cancer (eBC) Patients

25 Real-world BRCA1/2 Testing Patterns in HER2–Negative Early- Stage Breast Cancer (eBC) Patients

Gieira S. Jones;Liam C. Lee;Erin Alwon;Brandon Wang;Poras Dave;Sandy English;Prateesh Varughese;Simon Blanc;Arthur Sillah
April 27th 2023
ArticleMedical Oncology
26 Subgroup Analysis of Patients With No Prior Chemotherapy in EMERALD: A Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), Vs Investigator’s Choice of Endocrine Monotherapy for ER+/HER2– Advanced/ Metastatic Breast Cancer (mBC)

26 Subgroup Analysis of Patients With No Prior Chemotherapy in EMERALD: A Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), Vs Investigator’s Choice of Endocrine Monotherapy for ER+/HER2– Advanced/ Metastatic Breast Cancer (mBC)

Virginia Kaklamani, MD, DSc;Aditya Bardia, MD, MPH;Phillippe Aftimos;Javier Cortes;Patrick Neven, MD, PhD;Alberto J. Montero;Joo Hyuk Sohn;Giulia Tonini;Krzysztof J. Grzegorzewski;François-Clément Bidard
April 27th 2023
ArticleMedical Oncology
27 TIP XMT-1660: A Phase 1b Trial of a B7-H4 Targeted Antibody- Drug Conjugate (ADC) in Breast, Endometrial, and Ovarian Cancers

27 TIP XMT-1660: A Phase 1b Trial of a B7-H4 Targeted Antibody- Drug Conjugate (ADC) in Breast, Endometrial, and Ovarian Cancers

Kevin Kalinsky, MD, MS;Alexander Spira, MD, PhD, FACP;Sylvia Adams;Nour Abuhadra;Antonio Giordano;Ritesh Parajuli;Heather Han;Amy Weise;Kate Josephs;Erika P. Hamilton, MD
April 27th 2023
ArticleMedical Oncology
28 Pooled Analysis of Post- Progression Treatments After Firstline Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer in the MONALEESA-2, -3, and -7 Studies

28 Pooled Analysis of Post- Progression Treatments After Firstline Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer in the MONALEESA-2, -3, and -7 Studies

Kevin Kalinsky, MD, MS;Erika P. Hamilton, MD;Laura Spring;Peter A. Fasching;Sandra Franco, MD;Richard De Boer;Javier Cortes;Dejan Juric;Aditya Bardia, MD, MPH;Sina Haftchenary;Agnes Lteif;Juan Pablo Zarate;Liyi Cen;Patrick Neven, MD, PhD
April 27th 2023
ArticleMedical Oncology
31 TIP TROPION-Breast03: Datopotamab Deruxtecan (Dato-DXd) ± Durvalumab vs Investigator’s Choice of Therapy (ICT) for Triple-Negative Breast Cancer (TNBC) with Residual Disease Following Neoadjuvant Therapy

31 TIP TROPION-Breast03: Datopotamab Deruxtecan (Dato-DXd) ± Durvalumab vs Investigator’s Choice of Therapy (ICT) for Triple-Negative Breast Cancer (TNBC) with Residual Disease Following Neoadjuvant Therapy

Aditya Bardia, MD, MPH;Lajos Pusztai, MD, DPhil;Kathy S. Albain, MD;Kevin Kalinsky, MD, MS;Dawn Herman;William Barlow;Claudine Isaacs, MD;Micah Maxwell;Nadia Harbeck, MD, PhD;Priyanka Sharma, MD
April 27th 2023
ArticleMedical Oncology
33 Real-world Patient Characteristics, Treatment Patterns, and Outcomes Among Patients With Metastatic Breast Cancer and BRCA Mutations Treated Off-label With Talazoparib

33 Real-world Patient Characteristics, Treatment Patterns, and Outcomes Among Patients With Metastatic Breast Cancer and BRCA Mutations Treated Off-label With Talazoparib

Reshma L. Mahtani, DO ;Jasmina Ivanova;Angelica Falkenstein;Alexander Niyazov;Joanne C. Ryan;Jonathan Kish;Ajeet Gajra;Parisa Asgarisabet;Kristin M. Zimmerman Savill
April 27th 2023
ArticleMedical Oncology
35 TIP A Pragmatic Clinical Trial to Determine the Best Treatment Decision in Relapsed Metastatic Breast Cancer With Discordant Tumor Receptors

35 TIP A Pragmatic Clinical Trial to Determine the Best Treatment Decision in Relapsed Metastatic Breast Cancer With Discordant Tumor Receptors

T. Allen Pannell, Jr.
April 27th 2023
ArticleMedical Oncology
37 Open-Label, Phase 2, Multicenter Study of Lasofoxifene (LAS) Combined With Abemaciclib (Abema) for Treating Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation After Progression on Prior Therapies

37 Open-Label, Phase 2, Multicenter Study of Lasofoxifene (LAS) Combined With Abemaciclib (Abema) for Treating Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation After Progression on Prior Therapies

David J. Portman;Senthil Damodaran;Paul V. Plourde;Halle C. F. Moore, MD;Ian C. Anderson
April 27th 2023
ArticleMedical Oncology
44 Results From the Phase 1/2 Study of Patritumab Deruxtecan (HER3-DXd), a HER3-Directed Antibody-Drug Conjugate (ADC), in Patients (pts) With HER3- Expressing Metastatic Breast Cancer (MBC)

44 Results From the Phase 1/2 Study of Patritumab Deruxtecan (HER3-DXd), a HER3-Directed Antibody-Drug Conjugate (ADC), in Patients (pts) With HER3- Expressing Metastatic Breast Cancer (MBC)

Ian E. Krop;Norikazu Masuda;Toru Mukohara;Shunji Takahashi;Takahiro Nakayama;Kenichi Inoue;Hiroji Iwata;Tatsuya Toyama;Yutaka Yamamoto;Damien Hansra;Masato Takahashi;Akihiko Osaki;Kumiko Koyama;Tatsuya Inoue;Takatoshi Yonekura;Joseph Mostillo;Shoichi Ohwada;Yoshimi Tanaka;David Sternberg;Kan Yonemori
April 27th 2023
ArticleMedical Oncology
48 Sacituzumab Govitecan (SG) Efficacy in Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2– Negative (HR+/HER2–) Metastatic Breast Cancer (mBC) by HER2 Immunohistochemistry (IHC) Status in the Phase 3 TROPiCS-02 Study

48 Sacituzumab Govitecan (SG) Efficacy in Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2– Negative (HR+/HER2–) Metastatic Breast Cancer (mBC) by HER2 Immunohistochemistry (IHC) Status in the Phase 3 TROPiCS-02 Study

Sara M. Tolaney, MD, MPH;Peter Schmid, MD;Javier Cortes;Frederik Marmé;Hope S. Rugo, MD;Mafalda Oliveira;Delphine Loirat;Komal Jhaveri;Oh Kyu Yoon;Monica Motwani;Hao Wang;Rosemary Delaney;Aditya Bardia, MD, MPH
April 27th 2023
ArticleMedical Oncology
50 Pooled Exploratory Analysis of Survival in Patients (pts) With HR+/ HER2− Advanced Breast Cancer (ABC) and Visceral Metastases (mets) Treated With Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Trials

50 Pooled Exploratory Analysis of Survival in Patients (pts) With HR+/ HER2− Advanced Breast Cancer (ABC) and Visceral Metastases (mets) Treated With Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Trials

Denise A. Yardley, MD;Yoon Sim Yap;Hamdy Abdel Azim;Richard De Boer;Mario Campone;Alistair Ring;Michelino De Laurentiis;Joyce A. O’Shaughnessy;Javier Cortes;Yogesh Chattar;Astrid Thuerigen;Juan Pablo Zarate;Liz Santarsiero
April 27th 2023
ArticleMedical Oncology
53 Overall Survival (OS) Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (pts) With HR+/ HER2− Metastatic Breast Cancer (mBC)

53 Overall Survival (OS) Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (pts) With HR+/ HER2− Metastatic Breast Cancer (mBC)

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Frederik Marmé;Javier Cortes;Peter Schmid, MD;Delphine Loirat;Olivier Trédan;Eva Ciruelos;Florence Dalenc;Patricia Gómez Pardo;Komal L. Jhaveri;Rosemary Delaney;Theresa Valdez;Hao Wang;Wendy Verret;Sara M. Tolaney, MD, MPH
April 27th 2023
ArticleMedical Oncology
55 TIP ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Women and Men With Metastatic Breast Cancer (mBC)

55 TIP ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Women and Men With Metastatic Breast Cancer (mBC)

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Javier Cortes;Giuseppe Curigliano;Erika P. Hamilton, MD;Sara A. Hurvitz, MD;Sibylle Loibl;Simona Scartoni;Tarek Sahmoud, MD;Krzysztof J. Grzegorzewski;Nassir Habboubi;Joyce A. O’Shaughnessy
April 27th 2023
ArticleMedical Oncology
12>